HIGHFDA DRUG

Graviti Pharmaceuticals Bupropion Hydrochloride XL 300 mg Recall Impacts 46,512 Bottles (2025)

Graviti Pharmaceuticals Private Limited manufactured Bupropion Hydrochloride Extended-Release Tablets XL 300 mg, distributed nationwide by Rising Pharma Holdings, Inc., in 46,512 bottles. The recall cites failed tablet specifications. Stop using the product immediately and contact the manufacturer or your healthcare provider for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
September 15, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
September 15, 2025
Hazard Level
HIGH
Brands
Bupropion Hydrochloride, Rising Pharma Holdings, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Bupropion Hydrochloride, Rising Pharma Holdings, Inc.
Product type
Bupropion Hydrochloride Extended-Release Tablet (XL) 300 mg
Model numbers
BPB124341A, Exp date: 10/2026
UPC codes
16571-862, 16571-863, 16571-862-03, 16571-862-09, 16571-862-50, 16571-862-10, 16571-862-12, 16571-863-03 +3 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    September 15, 2025

  2. Reported by FDA DRUG

    October 29, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Tablet/Capsule Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Graviti Pharmaceuticals Private Limited or your healthcare provider for guidance. Notification method: Letter

About This Product

Bupropion hydrochloride extended-release tablets are used as antidepressants and for smoking cessation support in certain regimens. The XL formulation provides a longer dosing interval for some patients.

Why This Is Dangerous

A manufacturing defect causing failed tablet specifications can lead to incorrect dosing or variable drug release, potentially impacting treatment effectiveness or safety.

Industry Context

This recall is not described as part of a broader industry pattern in the provided information.

Real-World Impact

Patients may experience treatment disruption or require dose adjustments if the product is not dosed as intended. The issue is a quality control problem rather than an immediate physical hazard.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle label for NDC 16571-863-03.
  2. Check batch BPB124341A on the bottle or packaging.
  3. Verify expiration date 10/2026.
  4. Confirm bottle count is 30 tablets per bottle and total quantity recalled 46,512.

Where to find product info

NDC and batch numbers are printed on the bottle label and packaging. The recall notice links to enforcement reports with details.

What timeline to expect

Recall status is ACTIVE as of the report date; refunds or replacements are not explicitly described in the notice. Follow manufacturer guidance for a回

If the manufacturer is unresponsive

  • Contact Graviti Pharmaceuticals Private Limited for guidance.
  • If the company is unresponsive, escalate to FDA MedWatch or the appropriate national regulatory body.

How to prevent similar issues

  • Always verify NDC, batch, and expiration before using prescription meds.
  • Buy Rx meds from licensed pharmacies only.
  • Keep a record of recalls and batch information for future reference.

Documentation advice

Keep recall notices, bottle packaging, receipts, and any correspondence with the manufacturer or distributor.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

NDC: 16571-863-03 Batch: BPB124341A Exp: 10/2026 Quantity recalled: 46,512 bottles Package: 30-count bottles, Rx Only Manufactured by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India Distributed by: Rising Pharma Holdings, Inc. Sold to: 1 distributor and 16 wholesalers/pharmacy retailers nationwide Recall date: 2025-09-15 Status: ACTIVE

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Batch BPB124341A
  • 1 distributor and 16 wholesalers/pharmacy retailers nationwide

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
BPB124341A
Exp date: 10/2026
UPC Codes
16571-862
16571-863
16571-862-03
+8 more
Affected States
ALL
Report Date
October 29, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE